Results 81 to 90 of about 21,275,692 (207)

Systemic treatment of non-small cell lung cancer brain metastases

Contemporary Oncology, 2016
In the systemic treatment of brain metastases from non-small cell lung cancer (BMF-NSCLC) chemo- and targeted therapy are used. Response rates after platinum-based chemotherapy, range from 23% to 45%.
Ida Cedrych, Maksymilian A. Kruczała, Tomasz Walasek, Jerzy Jakubowicz, Paweł Blecharz, Marian Reinfuss   +5 more
doaj   +1 more source

Non–Small Cell Lung Cancer [PDF]

Journal of the National Comprehensive Cancer Network, 2010
David S, Ettinger, Wallace, Akerley, Gerold, Bepler, Matthew G, Blum, Andrew, Chang, Richard T, Cheney, Lucian R, Chirieac, Thomas A, D'Amico, Todd L, Demmy, Apar Kishor P, Ganti, Ramaswamy, Govindan, Frederic W, Grannis, Thierry, Jahan, Mohammad, Jahanzeb, David H, Johnson, Anne, Kessinger, Ritsuko, Komaki, Feng-Ming, Kong, Mark G, Kris, Lee M, Krug, Quynh-Thu, Le, Inga T, Lennes, Renato, Martins, Janis, O'Malley, Raymond U, Osarogiagbon, Gregory A, Otterson, Jyoti D, Patel, Katherine M, Pisters, Karen, Reckamp, Gregory J, Riely, Eric, Rohren, George R, Simon, Scott J, Swanson, Douglas E, Wood, Stephen C, Yang   +34 more
openaire   +2 more sources

Mapping of Multiple DNA Gains and Losses in Primary Small Cell Lung Carcinomas by Comparative Genomic Hybridization [PDF]

, 1994
Comparative genomic hybridization was applied for a comprehensive screening of under- and overrepresentation of genetic material in 13 autoptic small cell lung cancer specimens.
Speicher, Michael R., Cremer, Thomas, Petersen, Iver, Ried, Thomas, Manoir, Stanislas du, Schröck, Evelin, Holtgreve-Grez, Heidi   +6 more
core   +1 more source

Non-Small Cell Lung Cancer: Screening, Diagnosis, and Staging [PDF]

, 2012
Lung cancer is the leading cause of cancer deaths worldwide. Tobacco consumption is the primary cause of lung cancer, accounting for more than 85% 90% of all lung cancer deaths.
Rocha, E., Ferreira, J. P., Marques, F., Magalhães, M., Ferreira, J.   +4 more
core  

Encephalitis in non-small-cell lung cancer

Pulmonology, 2021
M. Costa e Silva, E. Silva, A. Mendes, A. Barroso   +3 more
openaire   +4 more sources

Characterisation and modulation of drug resistance in lung cancer cell lines [PDF]

, 2010
Chemotherapy drug resistance is a major obstacle in the treatment of cancer. It can result from an increase in levels of cellular drug efflux pumps such as P-glycoprotein (P-gp).
Dunne, Gráinne
core   +2 more sources

New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond

Therapeutics and Clinical Risk Management, 2011
Bruno Gori1, Serena Ricciardi1, Alberto Fulvi1, Salvatore Intagliata2, Ester Del Signore1, Filippo de Marinis11Oncological-Pulmonary Unit 1st, San Camillo Hospital, Rome, Italy; 2Department of Medical Oncology, University Campus Bio-Medico, Rome ...
Gori B, Ricciardi S, Fulvi A, Intagliata S, Del Signore E, de Marinis F   +5 more
doaj  

Iterative surgical resections in non-small cell lung cancer

Polish Journal of Thoracic and Cardiovascular Surgery, 2022
Ahmet Ucvet, Serkan Yazgan, Ozgur Samancilar, Soner Gursoy, Ahmet Emin Erbaycu, Berna Komurcuoglu   +5 more
doaj   +1 more source

Expert Consensus on Adjuvant Therapy of Non-small Cell Lung Cancer from China Thoracic Surgeons (2018 Version)

Chinese Journal of Lung Cancer, 2018
Thoracic Surgery Committee on Adjuvant Therapy of Non-small Cell Lung Cancer
doaj   +1 more source

Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib

, 2017
Microtubule-binding agents, such as taxanes and vinca alkaloids, are used in the treatment of cancer. The limitations of these treatments, such as resistance to therapy and the need for intravenous administration, have encouraged the development of new ...
Tsai, A-C;Wang, C-Y;Liou, J-P;Pai, H-C;Hsiao, C-J;Chang, J-Y;Wang, J-C;Teng, C-M;Pan, S-L, 鄧哲明   +1 more
core   +1 more source